August 13, 2018
1 min read

Resistance did not affect SVR rates in trials of Vosevi for HCV

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Baseline resistance associated substitutions did not impact sustained virologic response among direct-acting antiviral-experienced patients who underwent hepatitis C therapy with Vosevi for 12 weeks, according to a recently published study.

“In contrast to the prior studies of regimens targeting two distinct HCV proteins, the presence of NS3, NS5A and/or NS5B NI RASs did not affect treatment outcome in DAA-experienced patients including those who were previously treated with NS5A inhibitors upon treatment with [Vosevi] for 12 weeks in phase 3 trials,” Christoph Sarrazin, MD, from the Goethe University Hospital in Frankfurt, Germany, and colleagues wrote.

Sarrazin and colleagues’ review included data from the POLARIS-1 and POLARIS-4 studies of Vosevi (sofosbuvir/velpatasvir/voxilaprevirfor, Gilead Sciences), which included patients with HCV genotype 1 through 6.

SVR rates were 96.8% or higher for patients with either or both NS3 and NS5A RASs and 97.7% or higher for patients without RASs, which was not significantly different.

In a subanalysis of patients who had experience with earlier generation pegylated interferon therapy, the researchers found SVR rates of 95.1% or higher among patients with NS3 RASs.

Additionally, despite RAS position among patients with NS5A RASs, patients achieved SVR rates of 97% or higher.

“NS5A inhibitors are a common component of DAA regimens and more recently developed agents have demonstrated pangenotypic activity,” Sarrazin and colleagues wrote. “These results show that daily treatment with the single-tablet regimen of [Vosevi] for 12 weeks is highly effective for a broad range of DAA-experienced patients infected with HCV of any genotype regardless the presence of RASs.” – by Talitha Benenett

Disclosure: Sarrazin reports he has received research or grant support from Abbott, Achillion, Astra, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, Janssen, Merck Sharp & Dohme, Qiagen, Roche and Siemens. Please see the full study for the other authors’ relevant financial disclosures.